Getinge announces date of 2013 Q4 report and conference call
GETINGE will issue its Q4 report for 2013 on Tuesday 28th of January 2014 at 13:00 CET, followed by a conference call at 15:00 CET, hosted by Johan Malmquist, CEO, and Ulf Grunander, CFO.
We invite fund managers, analysts and the media to participate in the conference call. Please see below details to join the conference:
Swedish dial in number: +46 (0) 8 5065 3936
UK dial in number: +44 (0) 20 3427 1906
US dial in number: +1 212 444 0896
Participant passcode: 8105339
Agenda
14:45 Call in to the conference
15:00 Review of the Q4 report
15:20 Q&A
16:00 End of conference
A recorded version of the conference can be accessed for 5 working days on the following number:
Sweden: +46 (0) 8 5051 3897
UK: +44 (0) 20 3427 0598
US: +1 347 366 9565
Code: 8105339
During the telephone conference a presentation will be held. To access the presentation, please use this link:
http://www.livemeeting.com/cc/premconfeurope/join?id=8105339&role=attend&pw=pw2760
Alternatively enter the VisionCast site and log into your meeting using the Meeting ID and Password below:
VisionCast: http://www.euvisioncast.com
Your Name: (Enter your name)
Web Meeting ID: 8105339
Web Meeting Password: pw2760
For more information, please contact:
Kornelia Rasmussen
Group Communications
Phone: +46 (0)10 335 5810
E-mail: kornelia.rasmussen@getinge.com
GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
Tags: